Silence Therapeutics Reports Strong Q1 2026 Results Amid Divesiran Trial Progress
UKPulse Local Desk
Silence Therapeutics has highlighted recent business achievements and reported its first quarter 2026 financial results, which show promising progress in its Phase 2 SANRECO trial of divesiran.
- Silence Therapeutics reports Q1 2026 revenue of GBP 1.5 million, a 25% increase year-on-year
- Divesiran, a first-in-class siRNA for polycythemia vera (PV), is on-track for topline results in August 2026
- The company's share price has shown a 15% increase in the past month, with a current market value of GBP 140 million
Silence Therapeutics, a UK-based biotechnology company, has reported its first quarter 2026 financial results, which show a 25% increase in revenue year-on-year, reaching GBP 1.5 million. The company has highlighted its recent business achievements, including the progress of its Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV). The trial is on-track for topline results in August 2026, which could have significant implications for the treatment of this rare blood disorder.
The company's financial results also show a net loss of GBP 23 million in Q1 2026, which is in line with expectations. Silence Therapeutics has stated that it has sufficient cash reserves to fund its ongoing operations and the continuation of its clinical trials. The company's share price has shown a 15% increase in the past month, with a current market value of GBP 140 million.
Why this matters: The progress of Silence Therapeutics' divesiran trial and the company's financial results are significant for UK investors, particularly those with interests in biotechnology and healthcare sectors.
What this means for you: This story may affect household budgets, bills, savings, benefits or financial planning depending on your circumstances. Check whether the change applies to you before making financial decisions.